EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance

Dae Hun Kim iD, Sungmin Zo iD, Su-Young Kim iD, Byung Woo Jhun iD

Annals of Laboratory Medicine · 2024

DOI: 10.3343/alm.2024.44.1.92 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Laboratory Medicine, 2024. Verfasst von Dae Hun Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, …. Hauptthemen laut MEDLINE: Clarithromycin, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited data are available regarding the in vitro activity of SPR719, a derivative of benzimidazole, against diverse nontuberculous mycobacteria (NTM) species. We investigated the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of SPR719 against clinical NTM isolates, including clarithromycin- and amikacin-resistant strains. NTM isolates were obtained from patients with NTM-pulmonary disease caused by various NTM species, including Mycobacterium avium complex, M. abscessus (subspecies abscessus and massiliense), M. kansasii, and M. fortuitum. Regardless of clarithromycin or amikacin resistance, the MIC and MBC values of SPR719 were comparable among these major pathogenic NTM species. In over 70% of the isolates, the MIC values were ≤2 μg/mL with MBC values of ≤4 μg/mL. The MIC and MBC values of M. kansasii were relatively lower than those of the other species with little difference between them, demonstrating the bactericidal properties of SPR719. The in vitro activity of SPR719 against major clinical NTM species suggests that SPR719 can serve as a novel treatment option for NTM-pulmonary disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClarithromycinMycobacterium Infections, NontuberculousHumansAmikacinNontuberculous MycobacteriaBenzimidazolesAnti-Bacterial Agents

Stichwörter der Autor:innen

AmikacinAnti-bacterial agentsBenzimidazolesClarithromycinLung diseasesMicrobial sensitivity tests

Substanzen

ClarithromycinAmikacinBenzimidazolesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Dae Hun Kim, Sungmin Zo, Su-Young Kim, Byung Woo Jhun

Zitieren

APA

Kim, D. H., Zo, S., Kim, S. Y., & Jhun, B. W. (2024). In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance. Annals of Laboratory Medicine. https://doi.org/10.3343/alm.2024.44.1.92

Vancouver

Kim DH, Zo S, Kim SY, Jhun BW. In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance. Annals of Laboratory Medicine. 2024. doi:10.3343/alm.2024.44.1.92

BibTeX
@article{Kim2024,
  author = {Kim, Dae Hun and Zo, Sungmin and Kim, Su-Young and Jhun, Byung Woo},
  title = {In Vitro Activity of Benzimidazole (SPR719) Against Clinical Isolates of Nontuberculous Mycobacteria With and Without Clarithromycin or Amikacin Resistance},
  journal = {Annals of Laboratory Medicine},
  year = {2024},
  doi = {10.3343/alm.2024.44.1.92}
}
Kostenlos starten →